Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Immunol ; 189(3): 1265-73, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22753937

ABSTRACT

Ab responses in early life are low and short-lived; therefore, induction of protective immunity requires repeated vaccinations. One of the major limitations in early-life immunity is delayed maturation of follicular dendritic cells (FDCs), which play a central role in mediating the germinal center (GC) reaction leading to production of Ab-secreting cells (AbSCs). We assessed whether a nontoxic mutant of Escherichia coli heat-labile enterotoxin (LT-K63) and CpG1826 as model adjuvants could accelerate FDC maturation and immune response in neonatal mice, using a pneumococcal polysaccharide of serotype 1 conjugated to tetanus toxoid (Pnc1-TT) as a model vaccine. In neonatal NMRI mice, a single dose of Pnc1-TT coadministered with LT-K63 enhanced Pnc1-TT-induced GC reaction. In contrast, CpG1826 had no effect. Accordingly, LT-K63, but not CpG1826, accelerated the maturation of FDC networks, detected by FDC-M2(+) staining, characteristic for adult-like FDCs. This coincided with migration of MOMA-1(+) macrophages into the GCs that can enhance GC reaction and B cell activation. The FDC-M2(+) FDC networks colocalized with enhanced expression of TNF-α, which is critical for the maintenance of mature FDCs and is poorly expressed in neonates. The accelerated maturation of FDC networks correlated with increased frequency and prolonged persistence of polysaccharide- and protein-specific IgG(+) AbSCs in spleen and bone marrow. Our data show for the first time, to our knowledge, that an adjuvant (LT-K63) can overcome delayed maturation of FDCs in neonates, enhance the GC reaction, and prolong the persistence of vaccine-specific AbSCs in the BM. These properties are attractive for parenteral vaccination in early life.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Antibodies, Bacterial/biosynthesis , Antibody-Producing Cells/immunology , Bacterial Toxins/therapeutic use , Cell Differentiation/immunology , Dendritic Cells, Follicular/immunology , Enterotoxins/therapeutic use , Escherichia coli Proteins/biosynthesis , Polysaccharides, Bacterial/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Animals, Newborn , Antibody-Producing Cells/microbiology , Antibody-Producing Cells/pathology , Bacterial Toxins/administration & dosage , CpG Islands/immunology , Dendritic Cells, Follicular/microbiology , Dendritic Cells, Follicular/pathology , Enterotoxins/administration & dosage , Escherichia coli Proteins/administration & dosage , Escherichia coli Proteins/therapeutic use , Mice , Mice, Inbred Strains , Oligodeoxyribonucleotides/administration & dosage , Oligodeoxyribonucleotides/therapeutic use , Polysaccharides, Bacterial/administration & dosage , Polysaccharides, Bacterial/therapeutic use , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/therapeutic use
2.
Vaccine ; 26(21): 2562-9, 2008 May 19.
Article in English | MEDLINE | ID: mdl-18423950

ABSTRACT

The innocuousness of the Brucella melitensis Rev 1 live attenuated vaccine strain has never been fully assessed in rams. The immunopathological responses and the kinetics and distribution of the infection induced by this strain were determined after subcutaneous or conjunctival vaccination in both young (3-4 months old) and adult (12 months old) rams. At regular intervals after vaccination the animals were bled for serological studies, and slaughtered for both pathological and bacteriological examinations. The serological response after conjunctival inoculation was of lower intensity and duration than that induced subcutaneously, being the differences more evident in young rams. No genital lesions were produced and genital organs and accessory sexual glands were never found infected, being Rev 1 infection restricted to lymph nodes and spleen. Immunostained Rev 1 bacteria were located intracellularly in plasmablasts, dendritic follicular cells and macrophages in the target lymph nodes, in which cellular hyperplasia was the dominant pathological response. Subcutaneous vaccination induced a generalized infection by 2 weeks after vaccination, being then restricted to the prescapular target lymph node. Infection after conjunctival vaccination was less generalized, being restricted essentially to the cranial lymph nodes. Rev 1 infection was fully cleared by 3 months after vaccination in all animals. These results confirm the innocuousness of B. melitensis Rev 1 vaccine in rams.


Subject(s)
Brucella Vaccine/adverse effects , Brucella melitensis/pathogenicity , Brucellosis/microbiology , Brucellosis/pathology , Sheep Diseases/microbiology , Sheep Diseases/pathology , Animals , Antibodies, Bacterial/blood , Brucella Vaccine/immunology , Brucella melitensis/immunology , Brucellosis/immunology , Dendritic Cells, Follicular/microbiology , Genitalia, Male/microbiology , Genitalia, Male/pathology , Injections, Subcutaneous , Lymph Nodes/microbiology , Lymph Nodes/pathology , Macrophages/microbiology , Male , Plasma Cells/microbiology , Sheep , Sheep Diseases/immunology , Spleen/microbiology , Spleen/pathology , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...